Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

Table 1 Baseline characteristics of the study patients

Parameter	Total sample (n = 174)	Men (n = 121)	Women (n = 53)	P value
Age, years, Ме (IQR)	45.2 ± 10.1	42.9 ± 8.7	50.7 ± 10.5	< 0.001
T2DM	54 (31.0)	35 (28.9)	19 (35.8)	0.466
AH	41 (23.6)	27 (22.3)	14 (26.4)	0.695
Smoking	58 (33.3)	45 (37.2)	13 (24.5)	0.146
Obesity, classes I-III	121 (69.5)	79 (65.3)	42 (79.2)	0.097
Metabolic syndrome, NCEP ATP III	79 (45.4)	45 (37.2)	34 (64.2)	0.002

Data are presented as mean ± SD or n (%). Me: Median; IQR: Interquartile range; T2DM: Type 2 diabetes mellitus; AH: Arterial hypertension; NCEP ATP III: National cholesterol education program adult treatment panel III.